<DOC>
	<DOCNO>NCT02553343</DOCNO>
	<brief_summary>The aim study assess safety immunogenicity two formulation high-dose quadrivalent influenza vaccine compare license high-dose trivalent influenza vaccine control healthy elderly subject age 65 year age . Primary objective : - To describe safety profile subject study group . - To demonstrate high-dose quadrivalent influenza vaccine induces immune response ( assessed HAI geometric mean titer ( GMTs ) non-inferior response induce licensed high-dose trivalent influenza vaccine 3 common virus strain 28 day post-vaccination . Secondary objective : - To describe post-vaccination immunogenicity 4 virus strain ( assessed seroconversion seroprotection ) subject receive high-dose quadrivalent influenza vaccine license high-dose trivalent influenza vaccine . - To describe post-vaccination immunogenicity 4 virus strain ( assessed GMTs , seroconversion , seroprotection ) subject receive high-dose quadrivalent influenza vaccine investigational high-dose trivalent influenza vaccine .</brief_summary>
	<brief_title>A Study Safety Immunogenicity High-Dose Quadrivalent Influenza Vaccine Subjects Aged 65 Years Older</brief_title>
	<detailed_description>All eligible participant randomize receive single injection either one high-dose quadrivalent influenza vaccine formulation one high-dose trivalent influenza vaccine Day 0 . They provide blood sample hemagglutination inhibition ( HAI ) test . Safety information solicit , unsolicited reaction , serious adverse event , include adverse event special interest collect trial .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged ≥ 65 year day inclusion Informed consent form sign date Able attend schedule visit comply trial procedure . Participation time trial enrollment ( 4 week precede trial vaccination ) plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week ( 28 day ) precede trial vaccination plan receipt vaccine prior Visit 2 Vaccination influenza past 6 month Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Thrombocytopenia bleed disorder , contraindicate IM vaccination base investigator 's judgment Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Substance abuse , opinion investigator , might interfere trial conduct completion Chronic illness , opinion investigator , stage might interfere trial conduct completion Identified Investigator employee Investigator trial center direct involvement propose trial , identify immediate family member ( i.e. , parent , spouse ) Investigator employee direct involvement propose trial Personal family history GuillainBarré syndrome Neoplastic disease hematologic malignancy ( except localize skin prostate cancer stable time vaccination absence therapy subject history neoplastic disease disease free ≥ 5 year ) Known allergy iodinate radiocontrast medium Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥ 38.0°C [ ≥ 100.4°F ] ) . A prospective subject include trial condition resolve febrile event subside .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Influenza</keyword>
	<keyword>High-Dose Quadrivalent Influenza Vaccine</keyword>
	<keyword>High-Dose Trivalent Influenza Vaccine</keyword>
</DOC>